JP2024521897A5 - - Google Patents
Info
- Publication number
- JP2024521897A5 JP2024521897A5 JP2023574349A JP2023574349A JP2024521897A5 JP 2024521897 A5 JP2024521897 A5 JP 2024521897A5 JP 2023574349 A JP2023574349 A JP 2023574349A JP 2023574349 A JP2023574349 A JP 2023574349A JP 2024521897 A5 JP2024521897 A5 JP 2024521897A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- formula
- ribonucleoside
- items
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195993P | 2021-06-02 | 2021-06-02 | |
| US63/195,993 | 2021-06-02 | ||
| PCT/US2022/032014 WO2022256565A2 (en) | 2021-06-02 | 2022-06-02 | Compositions and methods for delivering therapeutic oligonucleotides to the central nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521897A JP2024521897A (ja) | 2024-06-04 |
| JP2024521897A5 true JP2024521897A5 (enExample) | 2025-05-28 |
Family
ID=84324589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574349A Pending JP2024521897A (ja) | 2021-06-02 | 2022-06-02 | 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240287526A1 (enExample) |
| EP (1) | EP4346845A4 (enExample) |
| JP (1) | JP2024521897A (enExample) |
| KR (1) | KR20240038930A (enExample) |
| CN (1) | CN117795069A (enExample) |
| AU (1) | AU2022286420A1 (enExample) |
| CA (1) | CA3222212A1 (enExample) |
| IL (1) | IL308994A (enExample) |
| WO (1) | WO2022256565A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024073595A2 (en) * | 2022-09-28 | 2024-04-04 | Atalanta Therapeutics, Inc. | Compositions and methods for treatment of huntington's disease |
| CN118202055A (zh) * | 2023-02-17 | 2024-06-14 | 苏州时安生物技术有限公司 | 一种抑制SCN9A基因表达的siRNA、其药物组合物及用途 |
| CN121241143A (zh) * | 2023-03-23 | 2025-12-30 | 阿塔兰塔治疗公司 | 用于改善的基因沉默的组合物和方法 |
| WO2025111497A1 (en) * | 2023-11-21 | 2025-05-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating acute activation |
| WO2025193786A1 (en) * | 2024-03-12 | 2025-09-18 | University Of Massachusetts | Oligonucleotides for prnp modulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004042024A2 (en) * | 2002-11-01 | 2004-05-21 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA |
| WO2011017297A2 (en) * | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
| JP5775581B2 (ja) * | 2010-08-20 | 2015-09-09 | レプリコール インコーポレーティッド | オリゴヌクレオチドキレート錯体 |
| CN102659495B (zh) * | 2012-04-25 | 2014-02-26 | 天津大学 | 利用寡核苷酸拆分手性药物的方法 |
| RU2668136C2 (ru) * | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| WO2015125147A1 (en) * | 2014-02-20 | 2015-08-27 | B. G. Negev Technologies And Applications Ltd | Anionic polyplexes for use in the delivery of nucleic acids |
| WO2017132669A1 (en) * | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| US20200339982A1 (en) * | 2017-12-22 | 2020-10-29 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorodithioate internucleoside linkage |
-
2022
- 2022-06-02 JP JP2023574349A patent/JP2024521897A/ja active Pending
- 2022-06-02 IL IL308994A patent/IL308994A/en unknown
- 2022-06-02 CA CA3222212A patent/CA3222212A1/en active Pending
- 2022-06-02 CN CN202280052900.3A patent/CN117795069A/zh active Pending
- 2022-06-02 US US18/566,983 patent/US20240287526A1/en active Pending
- 2022-06-02 AU AU2022286420A patent/AU2022286420A1/en active Pending
- 2022-06-02 WO PCT/US2022/032014 patent/WO2022256565A2/en not_active Ceased
- 2022-06-02 KR KR1020237045431A patent/KR20240038930A/ko active Pending
- 2022-06-02 EP EP22816877.9A patent/EP4346845A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230024153A1 (en) | Blood-brain barrier permeable heteroduplex nucleic acid | |
| CA2809637C (en) | Antisense nucleic acids | |
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2021507686A5 (enExample) | ||
| JP2024511473A5 (enExample) | ||
| JP2018528781A5 (enExample) | ||
| JP2022520986A5 (enExample) | ||
| JP7724259B2 (ja) | 新規のチオホスホラミダイト | |
| JP2024041845A (ja) | ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド | |
| EP3769769A1 (en) | Nucleic acid with reduced toxicity | |
| JP2021515784A5 (enExample) | ||
| JP2023518268A5 (enExample) | ||
| CN120129749A (zh) | 靶向微管相关蛋白TAU核酸的siRNA组合物和方法 | |
| CN114901823A (zh) | 诱导外显子50的跳读的反义核酸 | |
| JP7737667B2 (ja) | 核酸複合体 | |
| JP2024041886A (ja) | ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド | |
| JP2024542738A5 (enExample) | ||
| JP2025518487A5 (enExample) | ||
| JP2024512612A5 (enExample) | ||
| US20240287512A1 (en) | Lipid conjugation for targeting neurons of the central nervous system | |
| TW202335674A (zh) | 靶定中樞神經系統的星狀細胞之脂質結合物 | |
| TW202340462A (zh) | 靶定中樞神經系統的寡樹突細胞之脂質結合物 | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| US20260132400A1 (en) | Stabilized rna agents | |
| CN120569474A (zh) | 用于治疗亨廷顿氏病的组合物和方法 |